DEFERIPRONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H9NO2
Molecular Weight	139.1519
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C=CC(=O)C(O)=C1C

InChI

InChIKey=TZXKOCQBRNJULO-UHFFFAOYSA-N

InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3

HIDE SMILES / InChI

Molecular Formula	C7H9NO2
Molecular Weight	139.1519
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf
Curator's Comment: description was created based on several sources, including https://pubchem.ncbi.nlm.nih.gov/compound/deferiprone#section=Top; http://www.ncbi.nlm.nih.gov/pubmed/12825969

Deferiprone (trade name Ferriprox) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is an orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. All the adverse effects of deferiprone are considered reversible, controllable and manageable. These include agranulocytosis with frequency of about 0.6%, neutropenia 6%, musculoskeletal and joint pains 15%, gastrointestinal complains 6% and zinc deficiency 1%.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Iron 18 Target ID: CHEMBL2363058 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf	Chelating Agent 142

Conditions

Condition	Modality	Targets	Highest Phase	Product
Thalassemia syndrome 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf	Secondary		Approved 8429	FERRIPROX Approved Use Indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival Launch Date 2011
Iron overload 4 Sources: http://www.webmd.com/drugs/2/drug-158383/deferiprone-oral/details/list-conditions	Primary		Approved 8429	FERRIPROX Approved Use Indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival. Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias. Launch Date 2011

C_max

Value	Dose	Analyte	Population
64.8 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27975237/	25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	DEFERIPRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
118.8 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum	Homo sapiens
150.8 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum	Homo sapiens
60.8 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum	Homo sapiens
35.2 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma	Homo sapiens population: healthy age: sex: food status:
51.4 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	50 mg/kg single, oral dose: 50 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma	Homo sapiens population: healthy age: sex: food status:
54.4 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	50 mg/kg single, oral dose: 50 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE plasma	Homo sapiens population: healthy age: sex: food status:
34.1 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE plasma	Homo sapiens population: healthy age: sex: food status:
30.6 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE serum	Homo sapiens
33.4 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE serum	Homo sapiens
43.3 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE serum	Homo sapiens

AUC

Value	Dose	Analyte	Population
15001 μM × min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27975237/	25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	DEFERIPRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
205.5 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma	Homo sapiens population: healthy age: sex: food status:
331.2 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	50 mg/kg single, oral dose: 50 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma	Homo sapiens population: healthy age: sex: food status:
152.1 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	50 mg/kg single, oral dose: 50 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE plasma	Homo sapiens population: healthy age: sex: food status:
95.4 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE plasma	Homo sapiens population: healthy age: sex: food status:

T_1/2

Value	Dose	Analyte	Population
168 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27975237/	25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	DEFERIPRONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.58 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum	Homo sapiens
2.58 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum	Homo sapiens
3.34999999999999 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE serum	Homo sapiens
2.5 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma	Homo sapiens population: healthy age: sex: food status:
2.6 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	50 mg/kg single, oral dose: 50 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE 3-O-BETA-D-GLUCURONIDE plasma	Homo sapiens population: healthy age: sex: food status:
1.8 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	50 mg/kg single, oral dose: 50 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE plasma	Homo sapiens population: healthy age: sex: food status:
1.8 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01860703	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE plasma	Homo sapiens population: healthy age: sex: food status:
1.77 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE serum	Homo sapiens
2.03 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE serum	Homo sapiens
2.2 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01770652	33 mg/kg single, oral dose: 33 mg/kg route of administration: oral experiment type: single co-administered:	DEFERIPRONE serum	Homo sapiens

Doses

Dose	Population	Adverse events
30 mg/kg 2 times / day multiple, oral Recommended Dose: 30 mg/kg, 2 times / day Route: oral Route: multiple Dose: 30 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31620867 Page: p.3	unhealthy, 29–71 n = 10 Health Status: unhealthy Condition: Infratentorial superficial siderosis Age Group: 29–71 Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/31620867 Page: p.3	Disc. AE: Neutropenic sepsis, Fatigue... AEs leading to discontinuation/dose reduction: Neutropenic sepsis (30%) Fatigue (10%) Sources: https://pubmed.ncbi.nlm.nih.gov/31620867 Page: p.3
100 mg/kg multiple, oral (max\|total daily dose) Recommended Dose: 100 mg/kg Route: oral Route: multiple Dose: 100 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/32470438 Page: e475	unhealthy n = 193 Health Status: unhealthy Condition: Transfusion-dependent haemoglobinopathies Sex: M+F Population Size: 193 Sources: https://pubmed.ncbi.nlm.nih.gov/32470438 Page: e475	Disc. AE: Arthralgia, Joint effusion... AEs leading to discontinuation/dose reduction: Arthralgia (non-serious) Joint effusion (non-serious) Nausea (non-serious) Abdominal discomfort (non-serious) Fatigue (non-serious) Joint swelling (non-serious) Epistaxis (non-serious) Upper respiratory tract infections (non-serious) Upper abdominal pain (non-serious) Vomiting (non-serious) Palpitation (non-serious) Sources: https://pubmed.ncbi.nlm.nih.gov/32470438 Page: e475
33 mg/kg 3 times / day multiple, oral (max) Recommended Dose: 33 mg/kg, 3 times / day Route: oral Route: multiple Dose: 33 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.3	unhealthy n = 642 Health Status: unhealthy Condition: Transfusional iron overload due to thalassemia syndromes Population Size: 642 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.3	Disc. AE: Aspartate aminotransferase increased, Alanine aminotransferase increased... AEs leading to discontinuation/dose reduction: Aspartate aminotransferase increased (0.78%) Alanine aminotransferase increased (0.16%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.3
33 mg/kg 3 times / day multiple, oral (max) Recommended Dose: 33 mg/kg, 3 times / day Route: oral Route: multiple Dose: 33 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.4	unhealthy n = 642 Health Status: unhealthy Condition: Transfusional iron overload due to thalassemia syndromes Population Size: 642 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.4	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (1.6%) Vomiting (1.6%) Abdominal pain (1.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.4
33 mg/kg 3 times / day multiple, oral (max) Recommended Dose: 33 mg/kg, 3 times / day Route: oral Route: multiple Dose: 33 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Transfusional iron overload due to thalassemia syndromes Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.1	Disc. AE: Agranulocytosis, Fetal damage... AEs leading to discontinuation/dose reduction: Agranulocytosis (grade 3-5) Fetal damage Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf Page: p.1
15 mg/kg 2 times / day steady, oral Dose: 15 mg/kg, 2 times / day Route: oral Route: steady Dose: 15 mg/kg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01741532	unhealthy n = 58 Health Status: unhealthy Condition: Pantothenate Kinase-associated Neurodegeneration Population Size: 58 Sources: https://clinicaltrials.gov/ct2/show/NCT01741532	Other AEs: Neutropenia, Intestinal dilatation... Other AEs: Neutropenia (serious, 5 patients) Intestinal dilatation (serious, 1 patient) Intestinal obstruction (serious, 1 patient) Volvulus (serious, 1 patient) Obstruction (serious, 1 patient) Pyrexia (serious, 1 patient) Bacterial disease carrier (serious, 1 patient) Bronchitis (serious, 2 patients) Device related infection (serious, 1 patient) Pneumonia (serious, 2 patients) Wound infection (serious, 1 patient) Chemical eye injury (serious, 1 patient) Postoperative ileus (serious, 1 patient) Toxicity to various agents (serious, 1 patient) Unintentional medical device removal (serious, 1 patient) Oromandibular dystonia (serious, 1 patient) Device malfunction (serious, 1 patient) Urinary bladder rupture (serious, 1 patient) Choking (serious, 1 patient) Cough (serious, 1 patient) Respiratory disorder (serious, 1 patient) Colectomy (serious, 1 patient) Intestinal anastomosis (serious, 1 patient) Intrathecal pump insertion (serious, 1 patient) Laparotomy (serious, 1 patient) Medical device battery replacement (serious, 2 patients) Tracheostomy (serious, 1 patient) Tracheostomy tube removal (serious, 1 patient) Wound treatment (serious, 1 patient) Thrombosis (serious, 1 patient) Anaemia (below serious, 12 patients) Influenza (below serious, 3 patients) Pain (below serious, 4 patients) Bronchitis (below serious, 7 patients) Nasopharyngitis (below serious, 11 patient) Rhinitis (below serious, 4 patients) Upper respiratory tract infection (below serious, 8 patients) Viral infection (below serious, 4 patients) Laceration (below serious, 6 patients) Body temperature increased (below serious, 3 patients) Neutrophil count decreased (below serious, 10 patients) Serum ferritin decreased (below serious, 19 patients) Iron deficiency (below serious, 9 patients) Arthralgia (below serious, 8 patients) Muscle spasms (below serious, 3 patients) Pain in extremity (below serious, 10 patients) Dystonia (below serious, 25 patients) Migraine (below serious, 3 patients) Urinary incontinence (below serious, 3 patients) Cough (below serious, 10 patients) Oropharyngeal pain (below serious, 9 patients) Rhinorrhoea (below serious, 4 patients) Hyperhidrosis (below serious, 3 patients) Rash (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01741532

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A1 110 CYP1A2 1524 CYP2E1 882	UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 291 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A5 55 UGT2B4 249 UGT2B7 389 UGT2B10 127 UGT2B15 203 UGT2B17 213 UGT2B28 63

Drug as perpetrator

Target	Modality	Activity
CYP1A1 218	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=68 Page: 68.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=68 Page: 68.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=68 Page: 68.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=68 Page: 68.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=68 Page: 68.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=68 Page: 68.0	no

Drug as victim

Target	Modality	Activity
UGT1A6 307	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=18, https://pubmed.ncbi.nlm.nih.gov/18971318/ Page: 18, 26, 27-28, 31, 33, 41	major
UGT1A10 291	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=31, https://pubmed.ncbi.nlm.nih.gov/18971318/ Page: 31.0	minor
UGT1A8 283	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=31, https://pubmed.ncbi.nlm.nih.gov/18971318/ Page: 31.0	minor
UGT1A9 380	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=31, https://pubmed.ncbi.nlm.nih.gov/18971318/ Page: 31.0	minor
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT1A5 55	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT2B10 127	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT2B17 213	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT2B28 63	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT2B4 249	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	no
UGT1A7 236	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	yes
UGT2B15 203	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	yes
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18971318/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/021825Orig1s000ClinPharmR.pdf#page=73 Page: 73.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:68554	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:68554
ChemicalBook	CB0308124	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0308124
MolPort	MolPort-001-792-505	https://www.molport.com/shop/molecule-link/MolPort-001-792-505
Selleck Chemicals	deferiprone	http://www.selleckchem.com/products/deferiprone.html
ZINC	ZINC000000006226	http://zinc15.docking.org/substances/ZINC000000006226
eMolecules	502935	https://www.emolecules.com/cgi-bin/more?vid=502935

PubMed

Title	Date	PubMed
Characterization of iron uptake from transferrin by murine endothelial cells.	2000	10865941
Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.	2001 Jul	11553264
Deferiprone or fatal iron toxic effects?	2001 Mar 17	11265977
[Iron overload and myelodysplastic syndromes].	2001 Oct	11729396
Chelation therapy in beta-thalassemia: an optimistic update.	2001 Oct	11605171
Antimalarial effect of iron chelators.	2002	12572998
Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.	2002	12373086
Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.	2002	11838274
A postmodern moral tale: the ethics of research relationships.	2002 Apr	12120283
An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.	2002 Apr 23	12015817
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.	2002 Aug 17	12241655
Experience with the oral iron chelator deferiprone in transfusion-dependent children.	2002 Dec	12661341
Treatment of thalassoemia--the current scenario.	2002 Feb	12206353
Iron regulation of hepatic macrophage TNFalpha expression.	2002 Feb 15	11841920
The deferiprone controversy: time to move on.	2002 Feb 19	11873923
Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone.	2002 Jan 15	11803042
Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.	2002 Jan 31	11806714
Different complexation properties of some hydroxy keto heterocycles toward beryllium(II) in aqueous solutions: experimental and theoretical studies.	2002 Jul 29	12132927
I beg to differ.	2002 Jul 9	12137065
Orally active iron chelators.	2002 Jun	12127956
Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis.	2002 Mar	11886438
News article on report about drug researcher was biased.	2002 Mar 9	11884337
Microbial growth-promotion activity of 3-hydroxymonoazine- and N-hydroxydiazine-type heterocycles.	2002 Sep	12235861
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.	2002 Sep 1	12176871
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.	2003	12825969
Clinical research: a tale of two studies.	2003	12813922
[Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].	2003	12778850
Do we need more iron-chelating drugs?	2003 Aug 9	12927446
Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.	2003 Dec	14687998
The Olivieri case.	2003 Feb 27	12606746
Patients' health or company profits? The commercialisation of academic research.	2003 Jan	12645227
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.	2003 Jan 11	12531619
Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.	2003 May	12779268
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.	2003 May	12745268
Treatment of cardiac iron overload in thalassemia major.	2003 May	12745264
Signaling role of intracellular iron in NF-kappaB activation.	2003 May 16	12637578
Labile plasma iron in iron overload: redox activity and susceptibility to chelation.	2003 Oct 1	12805056
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.	2003 Sep 1	12763939

Patents

Sample Use Guides

In Vivo Use Guide

25 mg/kg to 33 mg/kg body weight, orally, three times per day, for a total daily dose of 75 mg/kg to 99 mg/kg body weight.

Route of Administration: Oral

In Vitro Use Guide

Proliferating CD4+ T cells from control and RRMS subjects, cultured with or without IL-2, decreased in response to 75 μM deferiprone, although the extent of decreased proliferation of CD4+ T cells from RRMS subjects was less than for control subjects. Proliferating CD8+ T cells from control subjects, cultured with or without IL-2, also decreased in response to 75 μM deferiprone, and this decrease was seen in proliferating CD8+ T cells from RRMS cultured with IL-2.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:47:54 GMT 2023` Edited by `admin` on `Fri Dec 15 15:47:54 GMT 2023`
Record UNII	2BTY8KH53L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DEFERIPRONE

Official Name

English

4(1H)-PYRIDINONE, 3-HYDROXY-1,2-DIMETHYL-

Systematic Name

English

DEFERIPRONE [EP MONOGRAPH]

Common Name

English

NSC-758880

Code

English

L-1

Code

English

3-Hydroxy-1,2-dimethylpyridin-4(1H)-one

Systematic Name

English

APO-66

Code

English

DEFERIPRONE [MART.]

Common Name

English

Deferiprone [WHO-DD]

Common Name

English

L1

Code

English

DEFERIPRONE [ORANGE BOOK]

Common Name

English

3-HYDROXY-1,2-DIMETHYL-4(1H)-PYRIDONE

Systematic Name

English

deferiprone [INN]

Common Name

English

DEFERIPRONE [EMA EPAR]

Common Name

English

CP-20

Code

English

DN-180-01-AF

Code

English

DEFERIPRONE [VANDF]

Common Name

English

DN-18001AF

Code

English

CP20

Code

English

DEFERIPRONE [USAN]

Common Name

English

APO-066

Code

English

DEFERIPRONE [MI]

Common Name

English

DEFERIPRON

Common Name

English

PL1

Code

English

PL-1

Code

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/10/832